Počet záznamů: 1
Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases
- 1.
SYSNO ASEP 0368597 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases Tvůrce(i) Liebl, J. (DE)
Kryštof, Vladimír (UEB-Q) RID, ORCID
Vereb, G. (HU)
Takacs, L. (HU)
Strnad, Miroslav (UEB-Q) RID, ORCID
Pechan, P. (DE)
Havlíček, Libor (UEB-Q) RID, ORCID
Zatloukal, Marek (UEB-Q) ORCID
Fuerst, R. (DE)
Vollmar, A. M. (DE)
Zahler, S. (DE)Celkový počet autorů 11 Zdroj.dok. Angiogenesis - ISSN 0969-6970
Roč. 14, č. 3 (2011), s. 281-291Poč.str. 11 s. Jazyk dok. eng - angličtina Země vyd. NL - Nizozemsko Klíč. slova Angiogenesis ; Cdk ; Small molecule Cdk inhibitors ; Roscovitine Vědní obor RIV CE - Biochemie CEP GA204/08/0511 GA ČR - Grantová agentura ČR GA301/08/1649 GA ČR - Grantová agentura ČR CEZ AV0Z50380511 - UEB-Q (2005-2011) UT WOS 000293922300006 DOI 10.1007/s10456-011-9212-6 Anotace Small molecular inhibitors of Cyclin dependent kinases (Cdks) are currently being developed as anticancer therapeutics due to their antiproliferative properties. The purine Cdk specific inhibitor (R)-roscovitine (seliciclib, CYC202) represents one of the most promising of these compounds. It is currently evaluated in clinical trials concerning cancer therapy. Recently, we have shown that roscovitine exerts potent antiangiogenic effects and elucidated Cdk5 as a new player in angiogenesis. These findings introduce Cdk5 as novel target for antiangiogenic therapy, and Cdk5 inhibitors as an attractive therapeutic approach. Here, we present the antiangiogenic profile of 15 derivatives of roscovitine in vitro and in vivo and provide structure activity relationships of the roscovitine analogs. Pracoviště Ústav experimentální botaniky Kontakt David Klier, knihovna@ueb.cas.cz, Tel.: 220 390 469 Rok sběru 2012
Počet záznamů: 1